Cost-effectiveness of p24 antigen testing in preventing transfusion transmission of human immunodeficiency virus infection.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to H B Soloway.
Explore the source record for details and available documents.
Direct Laboratory Access (DLA) refers to a program whereby individuals who wish to have laboratory testing performed can avail themselves of such testing independently of a physician referral. DLA benefits both physicians and consumers. Physicians benefit by not having to invest time and office resources for consumers who do not seek medical intervention but rather who visit physicians for the sole purpose of obtaining permission to have laboratory tests performed. Consumers benefit by avoiding physician encounters they do not want, by receiving state-of-the-art laboratory testing they do want, and by avoiding the added expense and inconvenience of a physician office visit. DLA appeals to an anxious, educated, and somewhat affluent niche market. The program fills a void in the provision of health services while providing a small stream of revenue for laboratories.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A case of antithrombin-III (AT-III) deficiency was diagnosed on the basis of a diminished anticoagulant effect following the administration of heparin for cardiopulmonary bypass. The clinical evaluation and interpretation of a diminished response to heparin is discussed, as are considerations relative to the treatment of AT-III deficient persons whose disorder is not manifest until they are already anesthetized for cardiovascular bypass. The implications of AT-III deficiency relative to the mechanism of heparin rebound are also discussed.
Heparin monitoring during procedures involving cardiopulmonary bypass using the Bull protocol has been programmed using a microcomputer. The program displays the in-vivo heparin tolerance curve and the patient's effective plasma heparin level along this curve. It calculates the incremental dose of heparin necessary to achieve effective anticoagulation throughout the procedure. At the conclusion of the procedure, the dose of protamine needed to neutralize the "on-board" heparin is calculated and displayed. The program also flags unusual in-vivo heparin response curves and suggests to the operator possible explanations for these unusual responses. Training time to use the equipment and program is approximately 5 min.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.